

Efficacy of a new Vitamin E foam in prevention of early skin damage in patients undergoing radiotherapy

Submission date 08/11/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 10/11/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 10/11/2005	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Massimo Milani

Contact details
Via A. Nota 18
Milan
Italy
20126
+39 (0)253548007
massimo.milani@mipharm.it

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
VEF03/04

Study information

Scientific Title

Acronym

VEFOAM

Study objectives

To evaluate if a new topical formulation of Vitamin E is efficacious in the prevention of early skin damage during radiotherapy

Ethics approval required

Old ethics approval format

Ethics approval(s)

IRB approved study protocol in April 2004

Study design

Randomised parallel group Investigator blinded

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Prevention

Participant information sheet

Health condition(s) or problem(s) studied

Skin damage after radiotherapy

Interventions

Vitamin E foam topical application versus emollient standard cream

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Vitamin E foam

Primary outcome measure

1. Radiation Therapy Oncology Group (RTOG) skin score
2. Skin damage score

Secondary outcome measures

Tolerability

Overall study start date

01/03/2004

Completion date

01/06/2005

Eligibility**Key inclusion criteria**

Patients undergoing radiotherapy for breast or thoracic cancer

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

80

Key exclusion criteria

Known sensibility to topical Vitamin E

Date of first enrolment

01/03/2004

Date of final enrolment

01/06/2005

Locations**Countries of recruitment**

Italy

Study participating centre

Via A. Nota 18

Milan

Italy

20126

Sponsor information

Organisation

Mipharm (Italy)

Sponsor details

Via B. Quaranta 12

Milan

Italy

20126

+39 (0)253548007

massimo.milani@mipharm.it

Sponsor type

Industry

ROR

<https://ror.org/0441v1872>

Funder(s)

Funder type

Industry

Funder Name

Mipharm SPA

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration